Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods-Special Topic on Phage Display Technology-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods

Before diving into the methods, it is important to understand what a targeting peptide is. A targeting peptide is a short amino acid sequence, typically consisting of 5-15 amino acids, capable of binding specific targets with high affinity and specificity.

Compared to conventional antibodies, peptides are smaller and penetrate tissue barriers more effectively. They are less likely to trigger immune responses, offering higher safety, and can be conveniently subjected to various chemical modifications. For these reasons, finding the "right" peptide is critically important.

I. Classic Technology: Phage Display Technology

The core principle of phage display involves fusing the gene encoding an exogenous peptide or protein with a coat protein gene. As the phage assembles, the exogenous peptide is displayed on the phage surface, while its corresponding gene resides inside the phage. This creates a precise link between phenotype and genotype, providing the basis for downstream engineering.

Figure 1: M13 filamentous phage displaying OVA on pVIII^[3]

Screening Workflow:Conventional Workflow – Biopanning: Based on the affinity between the immobilized target molecule and the peptide library, multiple rounds of "binding-washing-amplification" enrich for phages capable of binding the target.

TekBiotech employs a blue/white colony screening method. First, a gene library is synthesized using technologies such as Trimer codon, NNK, or Error-prone PCR. The exogenous gene is specifically inserted into the N-terminus of the wild-type M13 phage P3 protein to maximize infectivity. Next, the constructed phage library is co-incubated with a "functional" target (e.g., an enzyme), followed by infection of bacteria and culture on plates containing specific substrates/indicators. If a phage binds/inhibits the target enzyme, the target enzyme's activity is inhibited, allowing normal bacterial growth and visible colony formation. Conversely, phages that cannot bind/inhibit the target enzyme leave the enzyme active, leading to bacterial death or an absence of color change (resulting in "blue" or "white" plaques depending on the specific design). Finally, these surviving clones are picked for sequencing.

Conventional phage biopanning offers large library capacity and is well-established. However, it is time-consuming, limited by bacterial transformation efficiency, cannot incorporate non-natural amino acids, and is primarily used for "discovering" novel candidate peptides. The wild-type M13 display method described for TekBiotech is particularly suitable for enzyme targets whose activity can be translated into a phenotypic color change. It enables one-step phenotypic screening, with a relatively simple and direct workflow, high infection efficiency, and potentially lower false positives due to its direct functional readout.

II. mRNA Display Technology

The essence of mRNA display is a "directed evolution" platform realized in a test tube, completely bypassing the constraints of cellular transformation efficiency. It locks the link between a protein's function (phenotype) and its encoding gene (genotype) through a covalent linkage mediated by puromycin. This allows efficient selection of protein molecules with desired functions from vast random sequence libraries through multiple rounds of "selection-amplification" cycles.

Figure 2: Formation of mRNA-protein fusions on the ribosome ^[1]

The workflow is analogous to classical phage display. The mRNA-peptide fusion library is incubated with the target, unbound molecules are washed away, and the mRNA genes corresponding to target-binding peptides are recovered and amplified via RT-PCR for the next round of screening or for sequencing analysis.

Figure 3: Complete workflow of mRNA display technology ^[2]

III. Peptide Array Technology

This technique uses microarray technology to immobilize hundreds or thousands of known-sequence peptides at high density on a solid support. A fluorescently labeled target protein is then flowed over the array surface. By measuring the fluorescence signal intensity, peptides that bind the target are rapidly identified. This technology is primarily used for candidate peptide validation, affinity comparison, and epitope mapping.

TekBiotech (Tianjin) Co., Ltd. , with its core expertise in phage display and yeast display antibody development services, is a high-tech enterprise committed to providing advanced "one-stop targeted peptide discovery and optimization" solutions to our clients. Our services cover the critical stages of early drug discovery: de novo targeting peptide discovery, lead peptide optimization, and customized screening solutions tailored to client needs to solve complex biological problems.

References

[1] Liu R, Barrick JE, Szostak JW, et al. Optimized synthesis of RNA-protein fusions for in vitro protein selection. Methods Enzymol. 2000;318:268-93.

[2] Hammond PW, Alpin J, Rise CE, et al. In vitro selection and characterization of Bcl-X(L)-binding proteins from a mix of tissue-specific mRNA display libraries. J Biol Chem. 2001;276(24):20898-906.

[3] Hess KL, Jewell CM. Phage display as a tool for vaccine and immunotherapy development. Bioeng Transl Med. 2019 Sep 18;5(1):e10142.

[4] Schmitz U, Versmold A, Kaufmann P, Frank HG. Phage display: a molecular tool for the generation of antibodies—a review. Placenta. 2000;21 Suppl A:S106-S112.

Previous:Revolutionary Advances in Single-Domain Antibody Development and Applications Next:None!